15
|
99
|
7nuiB |
Crystal structure of hla-b*08:01 in complex with elrsrywai viral peptide |
66
|
289
|
6zf7A |
Keap1 kelch domain bound to a small molecule inhibitor of the keap1-nrf2 protein-protein interaction |
67
|
289
|
6zezA |
Keap1 kelch domain bound to a small molecule inhibitor of the keap1-nrf2 protein-protein interaction |
65
|
290
|
6zf8A |
Keap1 kelch domain bound to a small molecule inhibitor of the keap1-nrf2 protein-protein interaction |
65
|
288
|
6zeyA |
Keap1 kelch domain bound to a small molecule inhibitor of the keap1-nrf2 protein-protein interaction |
69
|
289
|
6zf3A |
Keap1 kelch domain bound to a small molecule inhibitor of the keap1-nrf2 protein-protein interaction |
70
|
288
|
6zewA |
Keap1 kelch domain bound to a small molecule fragment |
65
|
288
|
6zf1A |
Keap1 kelch domain bound to a small molecule inhibitor of the keap1-nrf2 protein-protein interaction |
102
|
236
|
6yiaA |
14-3-3 sigma in complex with smad2 ps465 peptide |
66
|
288
|
6zf2A |
Keap1 kelch domain bound to a small molecule inhibitor of the keap1-nrf2 protein-protein interaction |
65
|
289
|
6zf5A |
Keap1 kelch domain bound to a small molecule inhibitor of the keap1-nrf2 protein-protein interaction |
103
|
236
|
6yicA |
14-3-3 sigma in complex with smad4 ps403 peptide |
99
|
236
|
6yibA |
14-3-3 sigma in complex with smad3 ps423 peptide |
67
|
289
|
6zexA |
Keap1 kelch domain bound to a small molecule fragment |
65
|
290
|
6zf6A |
Keap1 kelch domain bound to a small molecule inhibitor of the keap1-nrf2 protein-protein interaction |
73
|
276
|
7nuiA |
Crystal structure of hla-b*08:01 in complex with elrsrywai viral peptide |
64
|
289
|
6zf4A |
Keap1 kelch domain bound to a small molecule inhibitor of the keap1-nrf2 protein-protein interaction |
68
|
288
|
6zf0A |
Keap1 kelch domain bound to a small molecule inhibitor of the keap1-nrf2 protein-protein interaction |
51
|
126
|
7bevA |
Nmr structure of an optimized version of the first tpr domain of the human spag1 protein |
38
|
107
|
6yeuA |
Second eh domain of ateh1/pan1 |
99
|
236
|
6y7tA |
Engineered conjugation of lysine-specific molecular tweezers with exos derived peptidic inhibitor enhance affinity towards target protein 14-3-3 through ditopic binding |
1
|
10
|
6y7tD |
Engineered conjugation of lysine-specific molecular tweezers with exos derived peptidic inhibitor enhance affinity towards target protein 14-3-3 through ditopic binding |
87
|
306
|
7aqeA |
Structure of sars-cov-2 main protease bound to unc-2327 |
65
|
325
|
7co5B |
Htra-type protease algw with decapeptide |
72
|
329
|
7co7D |
Htra-type protease algws227a with decapeptide |
59
|
337
|
7co2A |
Htra-type protease algw with tripeptide |
83
|
303
|
7nevA |
Structure of the hemiacetal complex between the sars-cov-2 main protease and leupeptin |
43
|
128
|
7khhD |
Ternary complex of vhl/brd4-bd1/compound9 (4-(3,5-difluoropyridin-2-yl)-n-(11-(((s)-1-((2s,4r)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-11-oxoundecyl)-10-methyl-7-((methylsulfonyl)methyl)-11-oxo-3,4,10,11-tetrahydro-1h-1,4,10-triazadibenzo[cd,f]azulene-6-carboxamide) |
64
|
337
|
7co3A |
Htra-type protease algws227a with tripeptide |
26
|
96
|
7khhB |
Ternary complex of vhl/brd4-bd1/compound9 (4-(3,5-difluoropyridin-2-yl)-n-(11-(((s)-1-((2s,4r)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-11-oxoundecyl)-10-methyl-7-((methylsulfonyl)methyl)-11-oxo-3,4,10,11-tetrahydro-1h-1,4,10-triazadibenzo[cd,f]azulene-6-carboxamide) |
28
|
105
|
7khhA |
Ternary complex of vhl/brd4-bd1/compound9 (4-(3,5-difluoropyridin-2-yl)-n-(11-(((s)-1-((2s,4r)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-11-oxoundecyl)-10-methyl-7-((methylsulfonyl)methyl)-11-oxo-3,4,10,11-tetrahydro-1h-1,4,10-triazadibenzo[cd,f]azulene-6-carboxamide) |
42
|
148
|
7khhC |
Ternary complex of vhl/brd4-bd1/compound9 (4-(3,5-difluoropyridin-2-yl)-n-(11-(((s)-1-((2s,4r)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-11-oxoundecyl)-10-methyl-7-((methylsulfonyl)methyl)-11-oxo-3,4,10,11-tetrahydro-1h-1,4,10-triazadibenzo[cd,f]azulene-6-carboxamide) |
97
|
304
|
7dnoA |
Characterization of peptide ligands against wdr5 isolated using phage display technique |
0
|
6
|
7dnoC |
Characterization of peptide ligands against wdr5 isolated using phage display technique |
25
|
100
|
6wm1A |
Crystal structure of the grb2 sh2 domain in complex with a tripeptide: ac-py-ac6c-n-phenylpropyl |
24
|
101
|
6wo2A |
Crystal structure of the grb2 sh2 domain in complex with a tripeptide: ac-py-ac6c-n-isohexyl |
80
|
306
|
7ak4AA |
Structure of sars-cov-2 main protease bound to tretazicar. |
67
|
305
|
7aqjA |
Structure of sars-cov-2 main protease bound to triglycidyl isocyanurate. |
79
|
306
|
7aphAA |
Structure of sars-cov-2 main protease bound to tofogliflozin. |
82
|
306
|
7abuA |
Structure of sars-cov-2 main protease bound to rs102895 |
78
|
306
|
7ax6A |
Structure of sars-cov-2 main protease bound to glutathione isopropyl ester |
93
|
306
|
7aolA |
Structure of sars-cov-2 main protease bound to climbazole |
81
|
306
|
7awwA |
Structure of sars-cov-2 main protease bound to clonidine |
100
|
236
|
6yluA |
14-3-3sigma in complex with blnkpt152 phosphopeptide crystal structure |
98
|
236
|
6y58A |
Binary complex of 14-3-3 sigma (c38n) with the estrogen related receptor gamma (lbd) phosphopeptide |
98
|
235
|
6xy5A |
Ternary complex of 14-3-3 sigma (c38n), estrogen related receptor gamma (dbd) phosphopeptide, and disulfide ppi stabilizer 5 |
56
|
202
|
6zqqA |
Structure of the pmt3-mir domain with bound ligands |
80
|
306
|
7b83A |
Structure of sars-cov-2 main protease bound to pyrithione zinc |
95
|
236
|
7aewAAA |
14-3-3 sigma bound to bis-phosphorylated aminopeptidase n (apn, cd13) via canonical and non-canonical binding motifs |
88
|
306
|
7ay7A |
Structure of sars-cov-2 main protease bound to isofloxythepin |